CONFERENCE DAY TWO
MAY 20, 2025
7.30- 8.30: One-on-One Partnering portal meeting schedule starts, to sit down with key contacts up to an hour before day two starts.
8.25: Chair’s Opening Remarks
Developing Molecular Glue Degraders for Disease Targets not Druggable by PROTACs
8.30: Identifying Basal Ligase-Substrate Interactions for Molecular Glue Discovery
• Introducing AlphaSeq, enabling large-scale mapping of basal protein-protein interactions between therapeutically relevant substrates and a diverse repertoire of ligases and chaperones, providing a rich starting dataset for molecular glue discovery
• Sharing how machine learning models can integrate aggregate PPI data to predict neosubstrates and can leverage mutation analysis and structural insights to strengthen binding interfaces and uncover new therapeutic opportunities
• Showing how potentially gluable weak basal interactions can be leveraged for small molecule screening, using the AlphaSeq platform or complementary hit identification approaches
Randolph Lopez
Co-founder & Chief Technology Officer - A-Alpha Bio Inc.
8.50: Panel Discussion - Moving from Phenotypic Screening to Target Based Discovery
• Overview of panellist’s platform technologies to identify glues and degraders including scientific or technical hurdles
platforms address
• How can we combat the diversity in compounds when rationally designing novel candidates?
• What features define a protein as ligandable within a target space?
• How can we provide systematic and scalable screening panels; the debate between biochemical, phenotypical or
computational assays
Randolph Lopez
Co-founder & Chief Technology Officer - A-Alpha Bio Inc.
Giovanni Spagnolli
Chief Technology Officer - Sibylla Biotech srl
Brad Heckmann
Chief Scientific Officer - ASHA therapeutics
Arnout Schepers
CEO - TenAces Biosciences
9.20: Morning Break & Networking
9.30 - 11.00:Â One-to-One Partnering Meeting Opportunity
New Platforms for Protein Stabilization & Homeostasis: Demonstrating a Pharmacological Audit Trail
11.10: Developing Optimized Folding Interfering Degraders Targeting Cyclin D1
• Providing an overview of folding interference as a new modality to induce the degradation of a target protein
• Demonstrating that folding interfering degraders (FIDs) can be optimized to achieve high potency and desirable ADME properties
• Showing in vitro and in vivo characterization of FIDs acting on Cyclin D1
Giovanni Spagnolli
Chief Technology Officer - Sibylla Biotech srl
11.30: Phosphorylation-Inducing Chimeric Small Molecules – Pairing Kinases with Induced Proximity
• Enabling precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, trafficking, inactivation, and degradation
• Leveraging approach for treating cancer, and other critical immune, metabolic, and rare diseases
• Discussing collaborations to date, and future collaborations
Alexandra Joseph
Chief Scientific Officer - Photys Therapeutics
11.50: Expanding the Realm of Proximity to Achieve Biologically Novel Mechanisms
• Creating novel protein-protein interactions to achieve therapeutic goals not achievable by otherwise targeting individual proteins
• Localizing drug to tissue or cell level of specificity
• Addressing difficult-to-drug targets
Bret Williams
Senior Vice President of Research - Magnet Biomedicine
12.10: Lunch Break & Networking
12.30 – 1.30: One-to-One Partnering Meeting Opportunity
Why Are DACs an Attractive Technology for Pharma? Lowering Toxicity & Improving Efficacy with Increased Tissue Specificity
1.40: Targeted Protein Degraders as Next Generation Antibody Payloads
• Introducing Nurix’s expertise in targeted protein degradation and degrader-antibody conjugates
• The advantages of using degraders as antibody payloads                                                               • Discussing collaborations
Gwenn Hansen
Chief Scientific Officer - Nurix Therapeutics, Inc.
2.00: Precision ADCs: Engineering Novel Degrader Payloads for Improved Efficacy & Therapeutic Index
• Explaining key design attributes required for making TPDs effective as ADC payloads
• Approaching ADC payload optimization with a medicinal chemistry mindset
• Sharing initial proof-of-concept with a next gen anti-PSMAxSMARCA2/4 DAC for prostate cancer
Andrew Combs
Chief Chemistry Officer - Prelude Therapeutics​
2.20: Panel Discussion - Where do DACs Fit in? Discussing the Decision to Think about Degraders as Payloads
• What is it about small molecule degraders that lend themselves to making good payloads?
• Sharing parameters that allow a degrader protein to be distinct from a toxic payload
• What are some good targets for DACs?
• Collaboration potential between antibody engineering and protein degradation companies
Yue Xiong
Chief Scientific Officer - Cullgen Inc.
Andrew Combs
Chief Chemistry Officer - Prelude Therapeutics​
Gwenn Hansen
Chief Scientific Officer - Nurix Therapeutics, Inc.
2.50: Chair’s Closing Remarks
3.00: Conference Ends